Andreas Evers

ORCID

Publication Activity (10 Years)

Years Active: 2017-2024
Publications (10 Years): 10

Top Venues

Journal of medicinal chemistry

Biological chemistry

Molecular pharmaceutics

Pharmaceutics

This page only lists publications with an associated author ORCID identifier.

Publications

Paul Arras, Jasmin Zimmermann, Britta Lipinski, Bernhard Valldorf, Andreas Evers, Desislava Elter, Simon Krah, Achim Doerner, Enrico Guarnera, Vanessa Siegmund, Harald Kolmar, Lukas Pekar, Stefan Zielonka
Bovine ultralong CDR-H3 derived knob paratopes elicit potent TNF-α neutralization and enable the generation of novel adalimumab-based antibody architectures with augmented features. Biological chemistry 405 (7-8) (2024)
Paul Arras, Jasmin Zimmermann, Britta Lipinski, Bernhard Valldorf, Andreas Evers, Desislava Elter, Simon Krah, Achim Doerner, Enrico Guarnera, Vanessa Siegmund, Harald Kolmar, Lukas Pekar, Stefan Zielonka
Bovine ultralong CDR-H3 derived knob paratopes elicit potent TNF-α neutralization and enable the generation of novel adalimumab-based antibody architectures with augmented features. Biological chemistry (2024)
Paul Arras, Jasmin Zimmermann, Britta Lipinski, Bernhard Valldorf, Andreas Evers, Desislava Elter, Simon Krah, Achim Doerner, Enrico Guarnera, Vanessa Siegmund, Harald Kolmar, Lukas Pekar, Stefan Zielonka
Bovine ultralong CDR-H3 derived knob paratopes elicit potent TNF-α neutralization and enable the generation of novel adalimumab-based antibody architectures with augmented features. Biological chemistry 405 (7-8) (2024)
Andreas Evers, Shipra Malhotra, Wolf-Guido Bolick, Ahmad Najafian, Maria Borisovska, Shira Warszawski, Yves Fomekong Nanfack, Daniel Kuhn, Friedrich Rippmann, Alejandro Crespo, Vanita Sood
SUMO: In Silico Sequence Assessment Using Multiple Optimization Parameters. Methods in molecular biology (Clifton, N.J.) 2681 (2023)
Andreas Evers, Didier Clénet, Stefania Pfeiffer-Marek
Long-Term Stability Prediction for Developability Assessment of Biopharmaceutics Using Advanced Kinetic Modeling. Pharmaceutics 14 (2) (2022)
Martin Wolff, Anja Schüler, Klaus Gast, Robert Seckler, Andreas Evers, Stefania Pfeiffer-Marek, Michael Kurz, Norbert Nagel, Torsten Haack, Michael Wagner, Anja Thalhammer
Self-Assembly of Exendin-4-Derived Dual Peptide Agonists is Mediated by Acylation and Correlated to the Length of Conjugated Fatty Acyl Chains. Molecular pharmaceutics 17 (3) (2020)
Dan Sindhikara, Michael Wagner, Paraskevi Gkeka, Stefan Güssregen, Garima Tiwari, Gerhard Hessler, Engin Yapici, Ziyu Li, Andreas Evers
Automated Design of Macrocycles for Therapeutic Applications: From Small Molecules to Peptides and Proteins. Journal of medicinal chemistry 63 (20) (2020)
Andreas Evers, Martin Bossart, Stefania Pfeiffer-Marek, Ralf Elvert, Herman Schreuder, Michael Kurz, Siegfried Stengelin, Martin Lorenz, Andreas Herling, Anish Konkar, Ulrike Lukasczyk, Anja Pfenninger, Katrin Lorenz, Torsten Haack, Dieter Kadereit, Michael Wagner
Dual Glucagon-like Peptide 1 (GLP-1)/Glucagon Receptor Agonists Specifically Optimized for Multidose Formulations. Journal of medicinal chemistry 61 (13) (2018)
Andreas Evers, Torsten Haack, Martin Lorenz, Martin Bossart, Ralf Elvert, Bernd Henkel, Siegfried Stengelin, Michael Kurz, Maike Glien, Angela Dudda, Katrin Lorenz, Dieter Kadereit, Michael Wagner
Design of Novel Exendin-Based Dual Glucagon-like Peptide 1 (GLP-1)/Glucagon Receptor Agonists. Journal of medicinal chemistry 60 (10) (2017)
Andreas Evers, Torsten Haack, Martin Lorenz, Martin Bossart, Ralf Elvert, Bernd Henkel, Siegfried Stengelin, Michael Kurz, Maike Glien, Angela Dudda, Katrin Lorenz, Dieter Kadereit, Michael Wagner
Correction to Design of Novel Exendin-Based Dual Glucagon-like Peptide 1 (GLP-1)/Glucagon Receptor Agonist. Journal of medicinal chemistry 60 (13) (2017)

Andreas Evers.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Andreas Evers